Deltex Medical Group plc (LON:DEMG) has signed up two more US hospitals as customers for its surgical bloodflow monitors.
One of the new accounts is with a sister hospital to an existing US customer while the second comprises two linked facilities in Oklahoma.
Deltex has now signed up five US hospitals so far in the US in 2016 to make the total now 22.
Ewan Phillips, chief executive, added that trading this year has followed the pattern of growth in the US and elsewhere abroad offset by a decline in business with the NHS.
“Each additional platform account adds incremental momentum to our US business, where probe revenues in the year to date are running over 50% ahead of the corresponding period in 2015.
“We remain on track to achieve our target of opening 30 US hospital platform accounts in the middle part of the year."
He added that due one bulk of order worth £100,000 for probes in 2015 not being repeated second quarter growth rate will be below the underlying trend.
In the UK, oesophageal Doppler monitoring sales have fallen again but Deltex said results of two new ODM trials are due early June and early July that should highlight its benefits.
The company's key priority this year is to move the business through the cash break-even point at the operating level, Phillips added.